Unknown

Dataset Information

0

Galunisertib-Loaded Gelatin Methacryloyl Hydrogel Microneedle Patch for Cardiac Repair after Myocardial Infarction.


ABSTRACT: Uncontrolled and excessive fibrosis after myocardial infarction (MI) in the peri-infarct zone leads to left ventricular remodeling and deterioration of cardiac function. Inhibiting fibroblast activation during the mature phase of cardiac repair improves cardiac remodeling and function after MI. Here, we engineered a biocompatible microneedle (MN) patch using gelatin methacryloyl and loaded it with galunisertib, a transforming growth factor-beta (TGF-β)-specific inhibitor, to treat excessive cardiac fibrosis after MI. The MN patch could sustainably release galunisertib for more than 2 weeks and provide mechanical support for the fragile ventricular wall. After being applied to a rat model of MI, the galunisertib-loaded MN patch improved long-term cardiac function and reduced cardiac fibrosis by effectively inhibiting TGF-β depending on fibroblast activation. This strategy shows the potential of the MN patch as an advanced platform to locally deliver direct antifibrotic drugs to prevent myocardial fibrosis for the treatment of MI and the promotion of cardiac repair.

SUBMITTER: Chen H 

PROVIDER: S-EPMC9478946 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Galunisertib-Loaded Gelatin Methacryloyl Hydrogel Microneedle Patch for Cardiac Repair after Myocardial Infarction.

Chen Haiting H   Fan Lu L   Peng Ningxin N   Yin Yong Y   Mu Dan D   Wang Jun J   Meng Ran R   Xie Jun J  

ACS applied materials & interfaces 20220829 36


Uncontrolled and excessive fibrosis after myocardial infarction (MI) in the peri-infarct zone leads to left ventricular remodeling and deterioration of cardiac function. Inhibiting fibroblast activation during the mature phase of cardiac repair improves cardiac remodeling and function after MI. Here, we engineered a biocompatible microneedle (MN) patch using gelatin methacryloyl and loaded it with galunisertib, a transforming growth factor-beta (TGF-β)-specific inhibitor, to treat excessive card  ...[more]

Similar Datasets

| S-EPMC6261659 | biostudies-literature
| S-EPMC7464529 | biostudies-literature
| S-EPMC11656367 | biostudies-literature
| S-EPMC7182487 | biostudies-literature
2023-01-01 | GSE201196 | GEO
| S-EPMC5056724 | biostudies-literature
| S-EPMC7462883 | biostudies-literature
| S-EPMC9330234 | biostudies-literature
| S-EPMC7941201 | biostudies-literature